Abstract
OBJECTIVE: Human body fat mass is to a large extent genetically determined, but little is known about the susceptibility genes for common obesity. Interleukin-6 (IL-6) suppresses body fat mass in rodents, and IL-6 treatment increases energy expenditure in both rodents and humans. The −174 G/C single-nucleotide polymorphism (SNP) in the IL-6 gene promoter is common in many populations, and −174 C-containing promoters have been found to be weaker enhancers of transcription. Moreover, a SNP at position −572 in the IL-6 promoter has recently been reported to affect transcription. The objective was to investigate the association between the IL-6 gene promoter SNPs and obesity.
DESIGN: Trans-sectional association study of IL-6 gene promoter SNPs and indices of obesity.
SUBJECTS: Two study populations, the larger one consisting of hypertensive individuals (mean age 57 y, 73% males, n=485) and the other consisting of 20 y younger nonobese healthy females (n=74).
MEASUREMENTS: Genotyping for the −174 IL-6 G/C and the −572 G/C SNPs, body mass index (BMI), serum leptin levels, serum IL-6 levels, C-reactive protein, fasting blood glucose and various blood lipids.
RESULTS: The common −174 C allele (fC=0.46), but not any −572 allele, was associated with higher BMI and higher serum leptin levels in both study populations. In the larger population, there were significant odds ratios for the association of CC (2.13) and GC (1.76) genotypes with overweight (BMI>25 kg/m2). Moreover, as the C allele was common, it accounted for a significant population-attributable risk of overweight (12%; CI 2–21%), although its average effect was modest in this sample.
CONCLUSION: Genetically determined individual differences in production of IL-6 may be relevant for the regulation of body fat mass.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Barsh GS, Farooqi IS, O'Rahilly S . Genetics of body-weight regulation. Nature 2000; 404: 644–651.
Stunkard AJ, Harris JR, Pedersen NL, McClearn GE . The body-mass index of twins who have been reared apart. N Engl J Med 1990; 322: 1483–1487.
Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P . Melanocortin-4 receptor mutations are a frequent, heterogeneous cause of morbid obesity. J Clin Invest 2000; 106: 253–262.
Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S . Clinical spectrum of obesity, mutations in the melanocortin 4 receptor gene. N Engl J Med 2003; 348: 1085–1095.
Butler AA, Cone RD . Knockout models resulting in the development of obesity. Trends Genet 2001; 17: S50–S54.
Wallenius V, Wallenius K, Ahrén B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson J-O . Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 2002; 8: 75–79.
Wallenius K, Wallenius VW, Sunter D, Dickson SL, Jansson J-O . Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Comm 2002; 293: 560–565.
Li G, Klein RL, Matheny M, King MA, Meyer EM, Scarpace PJ . Induction of uncoupling protein 1 by central interleukin-6 gene delivery is dependent on sympathetic innervation of brown adipose tissue, underlies one mechanism of body weight reduction in rats. Neuroscience 2002; 115: 879–889.
Hirano T . Interleukin 6, its receptor: ten years later. Int Rev Immunol 1998; 16: 249–284.
Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ . The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease, systolic blood pressure in healthy men. Eur Heart J 2001; 22: 2243–2252.
Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P . The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369–1376.
Terry CF, Loukaci V, Green FR . Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000; 275: 18138–18144.
Rivera-Chavez FA, Peters-Hybki DL, Barber RC, O'Keefe GE . Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock 2003; 20: 218–223.
Acalovschi D, Wiest T, Hartmann M, Farahmi M, Mansmann U, Auffarth GU, Grau AJ, Green FR, Grond-Ginsbach C, Schwaninger M . Multiple levels of regulation of the interleukin-6 system in stroke. Stroke 2003; 34: 1864–1869.
Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL . Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 2003; 88: 255–259.
Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE . Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–616.
Prince JA, Feuk L, Howell WM, Jobs M, Emahazion T, Blennow K, Brookes AJ . Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation. Genome Res 2001; 11: 152–162.
Fernandez-Real JM, Broch M, Vendrell J, Richart C, Ricart W . Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects (see comments). J Clin Endocrinol Metab 2000; 85: 1334–1339.
Esterbauer H, Schneitler C, Oberkofler H, Ebenbichler C, Paulweber B, Sandhofer F, Ladurner G, Hell E, Strosberg AD, Patsch JR, Krempler F, Patsch W . A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 2001; 28: 178–183.
Blom G . Statistical estimates and transformed beta variables. John Wiley & Sons Inc.: New York; 1958.
Geigy JRB . S.A. Geigy scientific tables. Ciba-Geigy Limited: Basle; 1982.
Kennedy A, Gettys TW, Watson P, Wallace P, Ganaway E, Pan Q, Garvey WT . The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab 1997; 82: 1293–1300.
Kazumi T, Kawaguchi A, Hirano T, Yoshino G . C-reactive protein in young, apparently healthy men: associations with serum leptin, QTc interval, and high-density lipoprotein-cholesterol. Metabolism 2003; 52: 1113–1116.
Rexrode KM, Pradhan A, Manson JE, Buring JE, Ridker PM . Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 2003; 13: 674–682.
Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW . Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196–4200.
Rothwell NJ, Busbridge NJ, Lefeuvre RA, Hardwick AJ, Gauldie J, Hopkins SJ . Interleukin-6 is a centrally acting endogenous pyrogen in the rat. Can J Physiol Pharmacol 1991; 69: 1465–1469.
Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP . Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 1997; 82: 4167–4170.
Stouthard JM, Romijn JA, Van der Poll T, Endert E, Klein S, Bakker PJ, Veenhof CH, Sauerwein HP . Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol 1995; 268: E813–E819.
Lyngso D, Simonsen L, Bulow J . Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J Physiol 2002; 543: 379–386.
Faldt J, Wernstedt I, Fitzgerald SM, Wallenius K, Bergstrom G, Jansson JO . Reduced exercise endurance in interleukin-6 deficient mice. Endocrinology 2004; 145: 2680–2686.
Kubaszek A, Pihlajamaki J, Punnonen K, Karhapaa P, Vauhkonen I, Laakso M . The C-174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. Diabetes 2003; 52: 558–561.
Georges JL, Loukaci V, Poirier O, Evans A, Luc G, Arveiler D, Ruidavets JB, Cambien F, Tiret L . Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ECTIM study. Etude Cas-Temoin de l'Infarctus du Myocarde. J Mol Med 2001; 79: 300–305.
Burzotta F, Iacoviello L, Di Castelnuovo A, Glieca F, Luciani N, Zamparelli R, Schiavello R, Donati MB, Maseri A, Possati G, Andreotti F . Relation of the −174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol 2001; 88: 1125–1128.
Villuendas G, San Millan JL, Sancho J, Escobar-Morreale HF . The −597 G–>A and −174 G–>C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab 2002; 87: 1134–1141.
Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, Lowe GD, Humphries SE . Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001; 21: 1458–1463.
Nagaraju K, Raben N, Merritt G, Loeffler L, Kirk K, Plotz P . A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 1998; 113: 407–414.
Sothern RB, Roitman-Johnson B, Kanabrocki EL, Yager JG, Roodell MM, Weatherbee JA, Young MR, Nenchausky BM, Scheving LE . Circadian characteristics of circulating interleukin-6 in men. J Allergy Clin Immunol 1995; 95: 1029–1035.
Farooqi IS, Keogh JM, Kamath S, Jones S, Gibson WT, Trussell R, Jebb SA, Lip GY, O'Rahilly S . Partial leptin deficiency and human adiposity. Nature 2001; 414: 34–35.
Flier JS . Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116: 337–350.
Stenlof K, Wernstedt I, Fjallman T, Wallenius V, Wallenius K, Jansson JO . Interleukin-6 levels in the central nervous system are negatively correlated with fat mass in overweight/obese subjects. J Clin Endocrinol Metab 2003; 88: 4379–4383.
Fernandez-Real JM, Ricart W . Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24: 278–301.
Steensberg A, Fischer CP, Sacchetti M, Keller C, Osada T, Schjerling P, van Hall G, Febbraio MA, Pedersen BK . Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. J Physiol 2003; 548: 631–638.
Inoue H, Ogawa W, Ozaki M, Haga S, Matsumoto M, Furukawa K, Hashimoto N, Kido Y, Mori T, Sakaue H, Teshigawara K, Jin S, Iguchi H, Hiramatsu R, LeRoith D, Takeda K, Akira S, Kasuga M . Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 2004; 10: 168–174.
Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, Imai N, Suemura M, Kakehi T, Takagi N, Kishimoto T . Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003; 30: 1426–1435.
Cooper DN, Nussbaum RL, Krawczak M . Proposed guidelines for papers describing DNA polymorphism-disease associations. Hum Genet 2002; 110: 207–208.
Berthier MT, Paradis AM, Tchernof A, Bergeron J, Prud'homme D, Despres JP, Vohl MC . The interleukin 6-174G/C polymorphism is associated with indices of obesity in men. J Hum Genet 2003; 48: 14–19.
Acknowledgements
C Uggla, M Peterson and A-L Jirestedt are acknowledged for excellent technical work and suggestions. We also thank Gunnar Ekeroth for invaluable statistical advice and Professor Peter Arner for valid suggestions. This work was supported by grants from the Swedish Research Council (9894), the Swedish Medical Society, the Swedish Society for Medical Research, Vastra Gotaland Foundation, the Novo-Nordisk Foundation, the European Commission (Framework 6, Contract No. LSHM-CT-2003–503041) and the foundations of Bergwall, Thuring and Wiberg.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wernstedt, I., Eriksson, AL., Berndtsson, A. et al. A common polymorphism in the interleukin-6 gene promoter is associated with overweight. Int J Obes 28, 1272–1279 (2004). https://doi.org/10.1038/sj.ijo.0802763
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0802763
Keywords
This article is cited by
-
How Fatty Acids and Common Genetic Variants Together Affect the Inflammation of Adipose Tissue
Current Cardiovascular Risk Reports (2014)
-
Arbeit, Alter, Gesundheit und Erwerbsteilhabe
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (2013)
-
Variations in association of Interleukin 6 -G174C single nucleotide polymorphism with type 2 diabetes mellitus—a review
International Journal of Diabetes in Developing Countries (2013)
-
Genetic Polymorphisms in Adipokine Genes and the Risk of Obesity: A Systematic Review and Meta‐Analysis
Obesity (2012)
-
Body composition changes after laparoscopic adjustable gastric banding: what is the role of −174G>C interleukin-6 promoter gene polymorphism in the therapeutic strategy?
International Journal of Obesity (2012)